Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nkarta Inc (NQ: NKTX )

5.620 -0.130 (-2.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 378,338
Open 5.740
Bid (Size) 5.500 (5)
Ask (Size) 6.120 (3)
Prev. Close 5.750
Today's Range 5.570 - 5.810
52wk Range 4.830 - 20.35
Shares Outstanding 48,813,720
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
 
Via Benzinga

Performance

YTD
-6.80%
-6.80%
1 Month
+5.24%
+5.24%
3 Month
-51.68%
-51.68%
6 Month
-65.29%
-65.29%
1 Year
-42.06%
-42.06%

More News

Read More
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via TheNewswire.com
SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside
Via Benzinga
Expert Ratings for Nkarta
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via News Direct
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
Why Nkarta Stock (NKTX) Is Volatile During Monday's Session?
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
From Nkarta, Inc.
Via Globe NewsWire
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via Globe NewsWire
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
From Nkarta, Inc.
Via Globe NewsWire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Via InvestorPlace
Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
Via Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Via Benzinga
Positive Clinical Results Put Nkarta Stock on the Fast Track
Via InvestorPlace
Executives Buy More Than $32M Of 3 Stocks
Via Benzinga
How Is The Market Feeling About Nkarta Inc. - Common Stock?
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
Futures Slide Ahead Of Tech Earnings Deluge
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.